Literature DB >> 16508109

Crystallization and preliminary X-ray diffraction studies of a catechol-O-methyltransferase/inhibitor complex.

M L Rodrigues1, M J Bonifácio, P Soares-da-Silva, M A Carrondo, M Archer.   

Abstract

Inhibitors of the enzyme catechol-O-methyltransferase (COMT) are used as co-adjuvants in the therapy of Parkinson's disease. A recombinant form of the soluble cytosolic COMT from rat has been co-crystallized with a new potent inhibitor, BIA 8-176 [(3,4-dihydroxy-2-nitrophenyl)phenylmethanone], by the vapour-diffusion method using PEG 6K as precipitant. Crystals diffract to 1.6 A resolution on a synchrotron-radiation source and belong to the monoclinic space group P2(1), with unit-cell parameters a = 52.77, b = 79.63, c = 61.54 A, beta = 91.14 degrees.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16508109      PMCID： PMC1952394          DOI： 10.1107/S1744309104031197

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN： 1744-3091


  28 in total

Review 1.  Catechol-O-methyl transferase: pharmacological aspects and physiological role.

Authors:  H C Guldberg; C A Marsden
Journal:  Pharmacol Rev       Date:  1975-06       Impact factor: 25.468

2.  Enzymatic O-methylation of epinephrine and other catechols.

Authors:  J AXELROD; R TOMCHICK
Journal:  J Biol Chem       Date:  1958-09       Impact factor: 5.157

Review 3.  New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

Authors:  V Bonifati; G Meco
Journal:  Pharmacol Ther       Date:  1999-01       Impact factor: 12.310

Review 4.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

5.  Crystallization and preliminary crystallographic characterization of catechol-O-methyltransferase in complex with its cosubstrate and an inhibitor.

Authors:  M L Rodrigues; M Archer; M J Bonifácio; P Soares-da-Silva; M A Carrondo
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2001-05-25

6.  Expression and characterization of rat soluble catechol-O-methyltransferase fusion protein.

Authors:  M J Bonifácio; M A Vieira-Coelho; P Soares-da-Silva
Journal:  Protein Expr Purif       Date:  2001-10       Impact factor: 1.650

7.  Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT).

Authors:  B Masjost; P Ballmer; E Borroni; G Zürcher; F K Winkler; R Jakob-Roetne; F Diederich
Journal:  Chemistry       Date:  2000-03-17       Impact factor: 5.236

8.  Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application.

Authors:  Maria João Bonifácio; Margarida Archer; Maria L Rodrigues; Pedro M Matias; David A Learmonth; Maria Arménia Carrondo; Patrício Soares-Da-Silva
Journal:  Mol Pharmacol       Date:  2002-10       Impact factor: 4.436

Review 9.  Molecular pathways of neurodegeneration in Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

Review 10.  COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?

Authors:  C Warren Olanow; Fabrizio Stocchi
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.